{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033516","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.246214+00:00","generated_at":"2026-06-13T06:29:03.016675+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tivic Health raises ~$2.1M in public offering of 51.25M shares at $0.04/share","bullets":["Offering of 51,250,000 shares priced at $0.040 per share, gross proceeds ~$2.1M.","Net proceeds ~$1.9M after placement agent fees and expenses; intended for working capital.","Maxim Group acted as placement agent, receiving 8% cash fee ($164,000) and 2,050,000 warrants.","Placement agent warrants exercisable at $0.048/share for 5 years, 6-month lockout from closing.","Officers and directors entered 30-day lock-up on company securities following closing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033516","json":"https://secwatch.observer/filing/0000950170-23-033516.json","markdown":"https://secwatch.observer/filing/0000950170-23-033516.md","text":"https://secwatch.observer/filing/0000950170-23-033516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/0000950170-23-033516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/tivc-20230714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:29:03.016675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e0c87a691afa35f511f8e2d351371bedbbfef19","claim":"Valion Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-07-14).","evidence_excerpt":"Maxim Group LLC agreed to act as the placement agent (the “Placement Agent”), on a “reasonable best efforts” basis, in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/0000950170-23-033516-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"},{"claim_id":"f4b2a98f5f810ed2663e5d7c3cbc77308560b55d","claim":"Valion Bio, Inc. entered into Purchase Agreement with the investors named on the signature pages thereto (the “Purchasers”) valued at approximately $2.1 million (effective 2023-07-14).","evidence_excerpt":"On July 14, 2023, Tivic Health Systems, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the investors named on the signature pages thereto (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/0000950170-23-033516-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors named on the signature pages thereto (the “Purchasers”)"},{"label":"Value","value":"approximately $2.1 million"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}